Quo vadis human biomonitoring?
1Institute of Environmental and Occupational Toxicology, Airolo, CH-6780, Switzerland; Università della Svizzera Italiana (USI), Research and Transfer Service, CH-6900, Lugano, Switzerland; Walther-Straub-Institut für Pharmakologie und Toxikologie, Ludwig-Maximilians-Universität München, Nussbaumstrasse 26, D-80336, München, Germany.
Abstract:
The increasing presence of chemicals in commerce and their potential impacts on human and environmental health necessitate innovative approaches in exposure science, biomonitoring, and risk assessment. With over 450,000 synthetic chemicals currently in use and growing concerns about their ecological and human health effects, prioritizing chemicals for environmental risk assessment remains a critical objective. This review examines recent advancements in chemical prioritization, predictive toxicology, genomic databases, and biomonitoring techniques for evaluating health effects associated with chemical exposure. The significant progress achieved in recent years offers new opportunities for more comprehensive analyses of key factors influencing health outcomes. Currently, fewer than 1000 chemicals have been analyzed in environmental studies, and fewer than 450 chemicals have been assessed in biomonitoring studies. This limited number constrains the ability to fully characterize real-world exposures and their potential health implications. Urinary biomarkers are frequently utilized in biomonitoring research, yet their interpretation remains complex due to the high intra-individual variability of non-persistent chemicals. As a result, single-sample assessments may not always provide an accurate representation of chronic exposure levels, underscoring the importance of refining biomonitoring methodologies to strengthen the reliability of exposure-health associations. While biomonitoring effectively detects low-level exposures, linking these values to specific health outcomes is complex due to interactions between exposure, genetics, environmental factors, and individual health status. Furthermore, for many chronic diseases, long latency periods complicate direct exposure-disease correlations.
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies I: ABG and VBG
Arterial Blood Gas (ABG)
Arterial Blood Gas (ABG) studies are crucial for assessing the lungs' ability to supply oxygen and remove carbon dioxide, reflecting the patient's ventilation status. They also help understand the kidneys' capacity to...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...


